STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.
Read the full article on the original site.
Read Full Article